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Ovarian carcinomas (OCs) are poorly immunogenic and immune checkpoint inhibitors
(ICIs) have offered a modest benefit. In this study, high CD3+ T-cells and CD163+ tumor-
associated macrophages (TAMs) densities identify a subgroup of immune infiltrated high-
grade serous carcinomas (HGSCs) with better outcomes and superior response to
platinum-based therapies. On the contrary, in most clear cell carcinomas (CCCs)
showing poor prognosis and refractory to platinum, a high TAM density is associated
with low T cell frequency. Immune infiltrated HGSC are characterized by the 30-genes
signature (OC-IS30) covering immune activation and IFNg polarization and predicting good
prognosis (n = 312, TCGA). Immune infiltrated HGSC contain CXCL10 producing M1-
type TAM (IRF1+pSTAT1Y701+) in close proximity to T-cells. A fraction of these M1-type
TAM also co-expresses TREM2. M1-polarized TAM were barely detectable in T-cell poor
CCC, but identifiable across various immunogenic human cancers. Single cell RNA
sequencing data confirm the existence of a tumor-infiltrating CXCL10+IRF1+STAT1+
M1-type TAM overexpressing antigen processing and presentation gene programs.
Overall, this study highlights the clinical relevance of the CXCL10+IRF1+STAT1+
macrophage subset as biomarker for intratumoral T-cell activation and therefore offers
a new tool to select patients more likely to respond to T-cell or macrophage-
targeted immunotherapies.
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INTRODUCTION
Ovarian carcinomas (OCs) (1) represent a heterogeneous group
with three main subtypes (high-grade serous carcinoma [HGSC],
clear cell carcinoma [CCC] and endometrioid carcinoma [EC])
distinct by microscopic findings and molecular features. High-
grade serous carcinoma (HGSC) represents the most common
and lethal subtype. Patients with HGSC usually present with
advanced disease involving the pelvic and peritoneal cavity
associated with malignant ascites; in addition, transcoelomic
metastases or distant spread can be observed at the diagnosis.
Standard treatment consists of primary upfront debulking
surgery followed by adjuvant cytotoxic platinum-taxane based
therapy (1, 2). Most of the patients initially respond to this front-
line approach; however, 70% relapses within three years. Therapy
resistance mechanisms include genomic instability, epigenetic
deregulation, and change in tumor microenvironment, leading
to the cancer outgrowth (3, 4). A fraction of patients is refractory
to platinum-based regimens and relapses early during treatment,
displaying a rapid fatal course (1).
Few improvements in clinical outcomes have been obtained
in OCs. Encouraging results have been achieved with the
introduction of inhibitors targeting poly (ADP-ribose)
polymerase (PARP), particularly effective in Homologous
Recombination Deficiency (HRD) positive cases (5). HRD is
detected in up to half of tumors due to inactivation of HRD genes
by mutations or promoter hypermethylation (6). PARP
inhibitors maintenance therapy improves progression-free
survival (PFS) in platinum-sensitive newly diagnosed and
recurrent OCs (7, 8). Immunotherapy based on immune
checkpoint inhibitors (ICIs), has shown clinical efficacy in solid
cancer (9). On the contrary, until now, the global response rate of
HGSC to ICIs resulted modest, ranging from 10 to 25%, thus
suggesting an urgent need for predictive biomarkers. It should be
noted that OCs are characterized by low mutational burden and
this could represent one of the possible explanations of lower
response rate to ICIs in comparison to other cancer types (10).
However, the recent combination of ICIs and PARP inhibitors in
HRD+ OCs has shown promising results (11), suggesting higher
intrinsic immunogenicity associated with the HRD group.
The composition, density, and functional orientation of the
immune contexture predict patient survival and response to
various treatments in different cancers (12) including OCs, the
latter being traditionally considered scarcely immunogenic. A set
of studies challenged this view and demonstrated that a subgroup
of OCs displays a higher CD3+ TILs density associated with
longer progression-free intervals and better survival in advanced-
stage OCs (13). These observations were subsequently confirmed
by others (14) and by a recent meta-analysis (15). In contrast to
TILs, the clinical significance of tumor-associated macrophages
(TAMs) is largely ignored with conflicting observations.
In the present study, we explored the tumor ecosystem of OCs
on archival whole tumor sections. Data indicate that high density
of CD3+ T-cells and CD163+ TAMs marks a consistent group of
immune infiltrated HGSC, stratifies patients with different
outcomes and correlates with a thirty-gene signature (OC-IS30)
containing among others IFNg-regulated genes. On the contrary,
in most CCCs a high TAM density is not combined with a
significant T-cell infiltration. By extending the analysis to The
Cancer Genome Atlas, OC-IS30 strongly predicts a favorable
outcome in a large cohort of HGSC. By immunohistochemistry
for pSTAT1 and IRF1 together with RNAscope-mediated
detection of CXCL10, we could identify an M1-type
macrophage (Mf) population associated with immune
infiltrated HGSC, but not CCC. We extended and confirmed
these findings to other cancer types by immunohistochemistry
and by an unbiased analysis of scRNAseq dataset.
MATERIALS AND METHODS
Collection of Patient Samples
Ninety-seven cases of ovarian carcinoma treated between 1999
and 2009 were identified from the archive files of the Department
of Pathology, ASST Spedali Civili of Brescia (Brescia, Italy) and
included in the study. Hematoxylin & Eosin (H&E) stained slides
were reviewed by an expert (LA) for appropriate classification
according to the WHO 4th Edition (2014). All patients were
treated and followed at the Division of Obstetrics and
Gynecology ASST Spedali Civili di Brescia, Brescia, Italy.
Clinical and pathology data are summarized in Table 1 and
the full dataset in Supplementary Table S1. The study was
approved by the local IRB (WW-IMMUNOCANCERhum, NP-
906, NP-1284).
Immunohistochemistry
Immunohistochemistry was performed on four-micron FFPE
tissue sections with anti-CD3 (clone LN10, 1:100) anti-CD163
(clone 10D6, 1:50, Thermo Scientific) and anti-CD303/BDCA2
(clone 124B3.13, 1:75, Dendritics) antibodies, recognizing
respectively T-cells, TAMs and plasmacytoid dendritic cells
(PDCs). CD3 and CD163 stains were performed on Bond Max
automatic immunostainer (Leica Biosystems). Immunostains for
anti-CSF-1R (clone FER216, 1:1,500, Millipore), anti-IRF-1 (clone
D5E4, 1:100, Cell Signaling), anti-phospho-STAT1 (clone Tyr701
rabbit, 1:500, Cell Signaling), TREM2 (anti-TREM2 antibody (clone
D8I4C, 1:100, Cell Signaling Technology) and Granzyme-B (anti-
GZMB antibody, clone GrB-7, 1:20, Dako) were performed
manually upon microwave or thermostat bath oven epitope
retrieval in ethylenediamine tetra-acetic acid (EDTA) buffer (pH
8.00). Immunoreaction was revealed by using Novolink Polymer
(Leica Microsistem) followed diaminobenzidine as chromogen and
with hematoxylin as nuclear counterstain. For double immunostain,
after completing the first immune reaction, the second was
visualized using Mach 4 MR-AP (Biocare Medical), followed by
Ferangie Blue.
RNAscope
To localize CXCL10 positive cells, tissues were analyzed with
RNAscope assay (Advanced Cell Diagnostics, Newark, CA, USA)
using RNAscope 2.5 HD Assay-RED kit and Hs-CXCL10-C2
probe (Cat No. 311851-C2) recognizing the nt 2 to 1,115 of the
CXCL10 reference sequence NM_001565. The sections from
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fixed human tissue blocks were treated following the
manufacturer’s instructions. Briefly, freshly cut 3 mm sections
were deparaffinized in xylene and treated with the peroxidase
block solution for 10 min at room temperature followed by the
retrieval solution for 15 min at 98°C and by protease plus at 40°C
for 30 min. Control probes included Hs-POLR2a-C2 (Cat No.
310451) and DapB-C2 (Cat No. 310043-C2). The hybridization
was performed for 2 h at 40°C. The signal was revealed using
RNAscope 2.5 HD Detection Reagent and FAST RED.
Combined RNAscope and immunohistochemistry (for CD163,
IRF1, Phospho-STAT1, CSFR1 and TREM2) were used to
identify the cellular source of CXCL10. To this end, CXCL10
detection by RNAscope was followed by immunoreaction was
visualized using Novolink Polymer (Leica Microsistem) followed
by DAB or using Mach 4 MR-AP (Biocare Medical) followed by
Ferangi Blue (Biocare Medical).
Digital Image Analysis
Cell density of selected immune populations was analyzed using
digital microscopy. The absolute cell count was quantified
automatically using a custom-programmed script in Cognition
Network Language based on the Definiens Cognition Network
Technology platform (Definiens AG, Munich, Germany). Briefly,
CD3, CD163, and BDCA2 stained slides were digitalized using
an Aperio ScanScope CS Slide Scanner (Aperio Technologies,
(Leica Biosystem, New Castle Ltd, UK) at 40× magnification and
analyzed using Tissue Studio 2.0 (Definiens AG). The
quantitative scoring algorithm was customized using
commercially available templates (Supplementary Figure S1).
The image analysis pipeline comprised segmentation of nucleus
objects and cell classification based on a pre-trained decision
tree, according to staining intensity. Immune cell counts were
expressed as the number of positive cells/mm2 of ovarian
cancer area.
RNA Extraction and Gene
Expression Analysis
A custom immune signature of 105 genes, selected on the basis of
a PubMed literature search, was devised for the digital transcript
counting, including targets for innate and adaptive immunity,
co-stimulatory or immune effector molecules, and chemokines
with their corresponding receptors (Supplementary Table S2).
TABLE 1 | Clinicopathological features of the entire cohort of patients.
Patient characteristics All HGSC CCC EC
n. (%) n. (%) n. (%) n. (%)
All 97 (100) 59 (61) 18 (19) 20 (21)
Age
median (IQR) 58 (49–69) 61 (49–70) 56 (49–68.25) 53.5 (46–60)
Menopause
no 31 (32) 16 (27) 6 (33) 9 (45)
yes 64 (66) 41 (69) 12 (67) 11 (55)
NA 2 (2) 2 (3) 0 (0) 0 (0)
FIGO Stage
I–II 37 (38) 7 (12) 13 (72) 17 (85)
III–IV 60 (62) 52 (88) 5 (28) 3 (15)
Residual tumor
No 52 (54) 18 (31) 15 (83) 20 (100)
Yes 44 (45) 41 (69) 3 (17) 0 (0)
NA 1 (1) 0 (0) 0 (0) 0 (0)
Peritoneal cytology
negative 38 (39) 12 (20) 11 (61) 15 (75)
positive 55 (57) 47 (80) 6 (33) 3 (15)
NA 4 (4) 0 (0) 1 (6) 2 (10)
Chemotherapy response
not response/partial 16 (16) 12 (20) 4 (22) 0 (0)
complete 77 (79) 46 (78) 14 (78) 17 (85)
NA 4 (4) 1 (2) 0 (0) 3 (15)
Platinum sensitivity
resistant 15 (15) 15 (25) 0 (0) 0 (0)
partial sensitive 16 (16) 9 (15) 6 (33) 1 (5)
sensitive 62 (64) 34 (58) 12 (67) 16 (80)
NA 4 (4) 1 (2) 0 (0) 3 (15)
Platinum re-eligibility
no 19 (32) 19 (32) – –
yes 39 (66) 39 (66) – –
NA 1 (2) 1 (2) – –
CD3 (cells/mm2)
mg 97 130 42 86
CD163 (cells/mm2)
mg 365 446 285 253
HGSC, High-Grade Serous Carcinoma; CCC, Clear Cell Carcinoma; EC, Endometrioid Carcinoma; IQR, interquartile range; NA, not available; mg, geometric mean.
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A representative formalin-fixed and paraffin-embedded (FFPE)
tumor block was retrieved from the biobank. Tissue was cut into
10/20 mm sections and treated with Deparaffinization Solution
(QIAGEN). RNA was extracted using Qiagen RNeasy FFPE kit
(QIAGEN). Total RNA concentration and proteins contamination
were determined by a Nanodrop spectrophotometer (Nanodrop
Technologies, Ambion, Waltham, MA, USA). Quality of RNA was
monitored using Agilent 2100 Bioanalyser System (AGILENT).
Total RNA (100 ng) was assayed on a nCounter platform using
NanoString technology (NanoString, Seattle, WA), testing the
whole set of 105 endogenous genes, five housekeeping genes, six
ERCC (External RNA Control Consortium) positive controls and
eight ERCC negative controls (Supplementary Table S2). Raw
mRNA counts were normalized applying a sample-specific
correction factor to all the target probes per manufacturer’s
recommendations (technical normalization with Positive
Controls Normalization spiked in every assay and biological
normalization using housekeeping genes). The resulting
normalized counts were used in downstream analyses. Pearson
correlation analysis between log2 IHC densities and log2 mRNA
Nanostring normalized counts were performed by Hommel
correction for multiple comparisons deriving the OC-IS30
Immune signature. A penalized linear ridge regression was
applied to the Z-scores OC-IS30 gene expression to weight the
signature for its application in external datasets. For the
Nanostring data heatmaps, the above values were turned into
Z-scores. For Nanostring gene expression analysis, normalization
and differential expression (DE) were performed with Nanostring
nCounter nSolverTM 4.0 (Nanostring MAN-C0019-08), with
Nanostring Advanced Analysis Module 2.0 plugin (Nanostring
MAN-10,030–03) following the Nanostring Gene Expression Data
Analysis Guidelines (Nanostring MAN-C0011-04).
External Cohort Validation (TCGA)
For external cohort in-silico analysis, publicly available HGSC
data from The Cancer Genome Atlas [TCGA-OV, N = 312 (6)]
have been considered. Records of cases with full annotation on
tumor stage, survival data, mutational status of BRCA1 and
BRCA2 genes (both germline and somatic) and tumor
mutational burden (TMB) were retrieved through the
Computational Biology Center Portal (cBio): http://www.
cbioportal.org/ and downloaded on 15th Feb 2020. Data of
mRNA expression profile (TCGA_eset) were downloaded
through the curated OvarianData v.1.24.0 R package (16)). The
TCGA dataset was investigated computing the OC-IS30 Immune
signature and the whole immune fraction applying CIBERSORTx
(17) using a signature matrix (18) able to compute the global
immune transcriptome. Raw counts for primary solid tumor
samples of further eight TCGA projects (TCGA-BLCA, TCGA-
BRCA, TCGA-COAD, TCGA-HNSC, TCGA-LUAD, TCGA-
LUSC, TCGA-SKCM, and TCGA-UCEC) were downloaded
from GDC Legacy Archive (hg19) using TCGAbiolinks
R/Bioconductor package. The FFPE samples were removed.
Normalized expression levels, by upper quartile normalization
measured in RSEM were obtained. Overall stage was included as
clinical variables and 4,496 cases, including the OV dataset, were
available for the analysis.
Generation of HumanMonocyte-Derived Mf
PBMCs were obtained from buffy coats of healthy volunteer
blood donors (courtesy of the Centro Trasfusionale, ASST
Spedali Civili, Brescia) by Ficoll–Paque (GE Healthcare,
Milano, Italy) density gradient centrifugation at 360×g for
30 min. Peripheral blood CD14+ monocytes were magnetically
sorted with human Pan Monocyte Isolation Kit (Cat. No. 130-
096-537, Miltenyi Biotec, Bergisch Gladbach, Germany)
following manufacturer’s instructions. Isolated monocytes (7 ×
105 cells/ml) were seeded in RPMI 1640 medium (Cat. No. 1-41-
F01-I Bioconcept, Allschwil, Swiss) supplemented with 10% FBS
(Biochrom GmbH, Berlin, Germany), GlutaMAX™-I (Cat. No.
35050-038, Life Technologies, Carlsbad, CA), 20 U/ml penicillin,
20 µg/ml streptomycin (Cat. No. 15070-063, Life Technologies,
Carlsbad, CA). After overnight culture, non-adherent cells were
removed by washing with DPBS (Cat. No. 14190-094, Life
Technologies, Carlsbad, CA) and adherent monocytes were
cultured over 7 days in the presence of 100 ng/ml human M-
CSF premium grade (Cat. No. 130-096-489, Miltenyi Biotec) to
generate macrophages (M0). The medium was not replaced
throughout the culture period. Macrophages polarization was
obtained by replacing culture medium with fresh RPMI 1640
medium supplemented with 10% FBS and containing 50 ng/ml
recombinant human IFN-g (Cat. No. 300-02, Peprotech, London,
UK) or 20 ng/ml recombinant human IFN-g (Peprotech) + 100
ng/ml LPS from Escherichia coli O55:B5 (Cat. No. L6529 Sigma-
Aldrich, St. Louis, MO) (for M1 polarization) or 20 ng/ml
Recombinant human IL-4 premium-grade (Cat. No. 130-093-
920, Miltenyi Biotec) or 20 ng/ml Recombinant human IL-10
research-grade (Cat. No. 130-093-948, Miltenyi Biotec) (for M2
polarization) for 4 or 18 h. M0 cultured with fresh medium
without polarization cytokines was used as control.
Cell-Block Preparation
Cell suspensions of macrophages were centrifuged for 10 min at
3,000 rpm. A solution of plasma (100 ml, kindly provided by
Centro Trasfusionale, ASST Spedali Civili, Brescia) and
HemosIL8 RecombiPlasTin 2G (200 ml, Instrumentation
Laboratory, Bedford Ma, USA, Cat. No. 0020003050) (1:2)
were added to cell pellets, mixed until the formation of a clot,
then placed into a labeled cassette. The specimen was fixed in
10% formalin for 1 h followed by paraffin inclusion.
qRT-PCR
IL-6, CXCL10 and COX2 mRNA targets were quantified by
reverse transcription-polymerase chain reaction (qRT-PCR)
assay using the Vii-A 7 Real-Time PCR System (Applied
Biosystems, Thermo Fisher Scientific, Waltham, MA, USA).
Total RNA was purified from M0, M1 and M2 macrophages
using the RNeasy® Mini Kit (Cat. No. 74104, Qiagen). The
cDNA was synthesized by iScript gDNA cDNA Synthesis kit
(Cat. No. 1725035, Bio-Rad Laboratories Inc., Hercules, CA,
U.S.A.) from 150 ng of total RNA, in a total volume of 20 ml.
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About 1 ml of the cDNA synthesis reaction was used for the
specific amplification of the target transcripts. The Ribosomal
Protein S18 (RPS18) transcript was used as normalization
control. The qPCR was performed in a total volume of 10 ml
with TaqMan® Universal Master Mix II (Cat. No. 4369016,
Applied Biosystems, Thermo Fisher Scientific) and the Gene
Expression Assay (Supplementary Table S3). The threshold
cycle (Ct) was determined for each sample and quantification
was performed using the comparative Ct method. DCt was
derived as CtTarget − CtHousekeeping and considered for
statistical analysis.
Western Blotting
The intracellular levels of targets and actin proteins were
determined by western blotting. Cells were washed, re-
suspended in RIPA lysis buffer (Cat. No. 89900, Pierce,
Thermo Fischer Scientific) with a Protease Inhibitor Cocktail
(Cat. No. 78440, Sigma-Aldrich) and sodium orthovanadate
(Na3VO4) (Cat. No. 450243, Sigma-Aldrich), and kept in ice
for 10 min. After 20 min centrifugation at 12,000×g at 4°C, the
supernatant was collected and protein concentration determined
by Bradford assay. A total of 20 mg of proteins was loaded on 4–
12%NuPAGE® Bis-TrisMini Gels (Cat. No. NP0335, Invitrogen™,
Thermo Fisher Scientific) under reducing condition and transferred
onto a PVDF membrane (Cat. No. LC2007, Invitrogen™, Thermo
Fisher Scientific). Membranes were incubated in the blocking
solution 5% BSA (Cat. No. A3059, Sigma-Aldrich) in T-TBS
(TBS, 0.05% Tween 20) (Cat. No. 28360, Invitrogen™, Thermo
Fisher Scientific) for 1 h at room temperature; subsequently
membranes were exposed to primary antibodies diluted in
blocking solution, for 16 h at 4°C. Primary antibodies are listed in
Supplementary Table S4. After washing in TBS-T, the blots were
incubated with the appropriate secondary antibody (anti-Rabbit
Cat. No. sc-2077 Santa Cruz Biotechnology, Inc., Dallas, TX,
USA), conjugated with horseradish peroxidase for 1 h at
room temperature. Immunoreactive proteins were detected by
SuperSignal™ West Pico Chemiluminescent Substrate (Cat. No.
34577, Thermo Fisher Scientific) and visualized by autoradiography.
Statistical Analysis
For histological, clinical, and pathological analysis the qualitative
variables were described as absolute and relative frequencies. We
considered overall survival (OS) and progression-free survival
(PFS). In the absence of any events, survivals were censored at
last follow-up visit. Qualitative variables were compared between
groups using Chi-square test, quantitative one by t-test, Mann–
Whitney test or ANOVA, and post-hoc pairwise comparisons as
appropriate. By evaluation of Q–Q plots and applying the
Shapiro–Wilk Test immune cells densities’ distribution
followed a log-normal distribution; for statistical analysis log2
values of densities were used. Median values of continuous
variables’ distributions were set as cut-offs for dichotomization.
Univariable and multivariable analyses were performed with Cox
proportional hazard models. For all analyses the proportional
hazards assumption was tested and verified; estimates were
reported as hazard ratio (H.R) with 95% Confidence Intervals
(CI). In all analyses a two-tailed P value <0.05 was considered
significant. GraphPad Prism (San Diego, CA, USA), and R
(version 3.6.2) were used for statistical analysis.
scRNAseq Data Analysis
Processing of the Pan-Cancer Blueprint dataset. We downloaded
the raw datasets and selected the myeloid cells dataset (using the
article annotation with the mention “Myeloid” in the cell type
metadata, 37,334 cells) of Qian et al. (19) from a web server
(http://blueprint.lambrechtslab.org). Cells were merged using the
Canonical Correlation Analysis (CCA) and the Mutual Nearest
Neighbors (MNN) algorithms and we selected the 5,000 most
variable genes (following the Seurat 3 pipeline). We next
performed Louvain graph-based clustering. At the resolution
0.6 we obtained 27 clusters. Eleven clusters (c1, 2, 3, 4, 5, 9, 10,
12, 18, 19, 26) expressed high levels of CD68 and were labeled
as macrophages.
RESULTS
Heterogeneity of T-Cells and TAMs
Immune Contexture in OC Subtypes
By digital image analysis on stained sections, we measured T-
cells and Mf immune-contexture in a retrospective cohort of OC
(n = 97) and explored associations (Figures 1A–I). To this end,
serial sections from a representative tumor area of primary OC
obtained from a single tissue block were stained for CD3 and
CD163. The density of T-cells resulted extremely variable
ranging from 2 to 2,967 cells/mm2 (mean 283 cells/mm2,
median 106 cells/mm2, IQR 34–311 cells/mm2); similarly,
CD163+ TAMs counts varied from 51 to 4,714 cells/mm2
(mean 529 cells/mm2, median 372 cells/mm2, IQR 224–704
cells/mm2). The full dataset is reported in Supplementary
Table S1. Both densities’ distribution followed a log-normal
distribution, log2 values of densities were thus used for
statistical analysis (Supplementary Figure S2). Subgroup
analysis among OCs with different histology indicates that
HGSCs are significantly more infiltrated by CD3 T-cells,
compared to CCCs (p = .02, Figure 1B) and by CD163+
TAMs, compared to ECs (p = .027, Figure 1C). Moreover,
the TAMs/T-cells ratio resulted significantly higher in the CCC
subtype compared to HGSC (p = .045) or to EC subtypes (p = .04,
Figure 1D). Both immune populations resulted highly correlated
(R = .77, p=<.0001) also when considering the OC subgroups
HGSC (R=.79, p<.0001), CCC (R=.74, p = .0002) and EC
(R = .70, p = .001) respectively (Figure 1E). As indicated by
double and triple stain for CD3, GZMB and CD163, T-cells/
TAM interactions were commonly observed in HGSCs
(Figures 1F, G, J, K) but not in CCCs (Figures 1H, I). This
analysis highlights differences in immune contexture between
OCs subtypes, with immune infiltrated HGSC and T-cell poor
CCC positioned at the extreme of a functional spectrum.
T-Cells and TAMs Immune-Contexture
Predict Outcome in HGSC
We focused our clinical correlation analysis on HGSCs, the more
represented OC subtype (Table 1). The mean log2 CD3
+ T-cells
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FIGURE 1 | Immune contexture in OCs by digital microscopy and interactions of CD3+ T-cells and CD163+ TAMs. (A) Sections are from four representative HGSCs
(case #72, #59, #57 and #75) and immunostained for CD3 and CD163, recognizing T-cells (left column) and tumor-associated macrophages (TAMs) (right column).
Case #72 and #59 are HGSCs with rich immune cell density, characterized by high CD3+ T-cells and CD163+ TAMs, intraepithelial and stromal infiltrates. In
opposition case #57 and #75 correspond to two HGSCs with low immune cell density, showing very low-number of CD3+ T-cells and CD163+ TAMs. Sections are
counterstained with hematoxylin. Images had been acquired form Digitalized slides using Aperio Image Scope (Leica Biosystems) Magnification 200×; scale bar
100 um. Box plots showing CD3+ T-cells (B) and CD163+ TAMs (C) densities in different OCs subtypes. Box-plots showing the ratio of CD163+/CD3+ densities (D).
Scatter plot (E) illustrating the correlation analysis between CD163+ and CD3+ immune cells’ densities in the whole cohort and among different OCs subtypes. P
values estimated by One-way ANOVA with Tukey’s correction for multiple comparisons in (B–D); R and P values estimated by Pearson correlation test in (E).
Sections from HGSCs (F, G, J, K) and CCCs (H, I) cases and immunostained as labeled, showing common interactions between T-cells and CD163+ TAMs
observed in HGSCs and not in CCCs; magnification: 400× (F–I), 600× (J, K); scale bar: 50 um (F–I); 33 um (J, K). HGSC, High Grade Serous Carcinoma; EC,
Endometrioid Carcinoma; CCC, Clear Cell Carcinoma.
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density was significantly higher in patients with low-risk features,
such as Stages I–II (p = 0.03) and negative peritoneal cytology
(p = 0.016). Moreover, a higher immune cells infiltrate was
associated with a better response to first-line treatment.
Specifically, a complete response to chemotherapy was
associated with higher CD3+ T-cells density (p = 0.04).
Moreover, platinum sensitivity and platinum re-eligibility were
associated either with higher CD3+ T-cell density (p = 0.008, p =
0.009) and CD163+ TAM density (p = 0.028, p = 0.031). We
further expanded this analysis by evaluating the relevance of the
immune contexture in terms of clinical outcome. To this end,
subgroups were defined using the median values of each immune
cell densities’ distributions as cut-offs (CD3Hi vs CD3Low and
CD163Hi vs CD163Lo). The univariate survival analysis, reported
in Supplementary Table S5, confirmed, both for OS and PFS
respectively, the association with worse prognosis of well-known
clinical variables as higher Stages III–IV (H.R. 10.56, p = .02;
H.R. 6.63, p = .009), macroscopic residual tumor (H.R. 7.15,
p <.001; H.R. 2.89, p = .002), and positive peritoneal cytology
(H.R. 4.25, p <.007; H.R. 4.41, p = .002). The CD163Hi group
experienced a better OS (H.R. 0.48, p = .019, Figure 2A) and
better PFS (H.R. 0.56, p = .042, Supplementary Figure S3A);
besides, the CD3Hi had a better OS (H.R. 0.35, p = .001,
Figure 2B and Supplementary Figure S3B).
As both T-cells and TAMs were associated with favorable
prognosis and were positively correlated, we further expanded
our analysis by identifying three additional groups, namely
the ImmunoscoreLoLo (CD3Lo and CD163Lo), the Immunoscore
HiLo/LoHi (CD3Hi and CD163Lo, or CD3Lo and CD163Hi) and the
ImmunoscoreHiHi (CD3Hi and CD163Hi) groups, as shown in the
Treemap (Figure 2C). A higher Immunoscore was associated with
both chemotherapy response (p = 0.04) and platinum sensitivity
(p = 0.03, Figures 2C, D). In addition, univariate survival analysis
showed a better OS (ImmunoscoreHiLo/LoHi: H.R. 0.17, p <0.001;
ImmunoscoreHiHi H.R. 0.28, p <0.001; Figure 2E) and PFS
(ImmunoscoreHiLo/LoHi: H.R. 0.23, p <0.001; ImmunoscoreHiHi
H.R. 0.41, p = 0.005; Supplementary Figure S3C and
Supplementary Table S5) for higher immunoscore compared to
ImmunoscoreLoLo as reference group. In term of OS, the
multivariable survival analysis (Figure 2F) confirmed a favorable
prognosis for ImmunoscoreHiHi (H.R. 0.35, p = 0.008) compared to
ImmunoscoreLoLo OCs; moreover, a better PFS was observed for
ImmunoscoreHiLo/LoHi (H.R. 0.40, p= 0.031) and ImmunoscoreHiHi
(H.R. 0.49, p = .037) groups compared to ImmunoscoreLoLo OCs
(SupplementaryFigureS3D).The immunoscore variablewas even
more relevant than others clinical covariates as Stage or positive
peritoneal cytology that lost the statistical significance in the
multivariable model.
OC-IS30 Immune Signature Marks Immune
Infiltrated OCs
We further expanded our findings by measuring the expression
of a custom immune signature in the OC cohort using
Nanostring technology. The custom immune signature
included one-hundred and five targets covering genes relevant
for innate and adaptive immunity, effector molecules, and
chemokine with their corresponding receptors (Supplementary
Table S2). Eighty-one cases were deemed suitable for
Nanostring-based gene expression analysis (GEA). A set of
healthy ovarian tissue (n = 12) was included as control group.
Differential expression analysis revealed a significant up-
regulation (adj. p-values <0.05) of a large set of targets in OCs
compared to controls (Supplementary Figure S4A). A
supervised analysis based on histology subgroups revealed lack
of significant differences for most of the targets (Supplementary
Figure S4B), with the exception of four targets including CSF1,
the latter significantly higher in HGSC and correlating with a
high density of CD163+ TAMs (Supplementary Table S6). To
extend the finding obtained by digital microscopy analysis, we
correlated the GEA of OCs cases with the corresponding T-cell
and TAMs density. Of technical relevance, among all 105 genes
of the tested signature, none was inversely correlated with
immune cells densities (Figure 3A). In addition, a set of thirty
genes (from here referred as OC-IS30) (Supplementary Table
S6) showed a significant direct positive correlation with CD3+ T-
cells or CD163+ TAMs tissue densities (adj. p-value <0.05)
(Figures 3B–D). This finding was confirmed and extended by
applying CIBERSORTx (17) to the external OV-TCGA dataset
using a signature matrix (18) able to compute T-cells and
macrophages (Figure 3E). Of note, the OC-IS30 gene set
contained targets relevant to T-cell attracting chemokines
(CXCL10, CXCL9, CXCL11, and CXCL16), immune effector
function (GZMA, GNLY, PRF1, GZMB, GZMH), Mf biology
(CSF1, CSF1R, CCL2, CCL4, and CD163), immune checkpoints
(IDO1, CTLA4, CD274, PDCD1LG2, and PDCD1) and
interferon signature (CXCL10, CXCL9, CXCL11, CXCL16,
CD274, IDO1, STAT1, MX1, OAS1). The latter finding suggest
an ongoing interferon response in immune infiltrated OCs; based
on very low density of PDCs infiltration in primary OC
(Supplementary Figure S5), our data are more consistent with
an IFNg signature.
OC-IS30 Predicts Favorable Outcome in
HGSC and Across Human Cancer Types
The clinical significance of OC-IS30 was tested in the external
OV-TCGA dataset (6) containing 312 HGSCs annotated in term
of clinical and molecular finding (Stage, Overall Survival,
mutational status of BRCA1 and BRCA2 genes, and tumor
mutational burden (TMB). OC-IS30 expression was not
significantly associated with tumor stage (p = 0.09), BRCA1-2
mutations (p = 0.098) or TMB (p = 0.08), as reported in
Supplementary Figures S6A–C. For the distribution of OC-
IS30 score the median value was set as cut-off point for
identification of rich (Hi) or poor (Lo) immune represented
group. The HiOC-IS30 group was associated with a better OS at
univariable analysis (H.R. 0.68, CI95% 0.50–0.91, p = 0.01,
Figure 4A), as well as using a multivariable model including
well known prognosticators (Figure 4B). Specifically, the
multivariable analysis confirmed the favorable prognostic
significance of OC-IS30-Hi (H.R 0.72, p = 0.036) independent
from BRCA1-2 mutations (H.R. 0.55, p = 0.004) and TMB (H.R.
0.72, p = 0.01); the positive combined effect of HiOC-IS30 and
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FIGURE 2 | Clinical significance of CD3+ T-cells and CD163+ TAMs density in HGSC. Univariable overall survival estimates (Kaplan–Meier method) according to
CD3+ T-cells (A) and CD163+ TAMs (B) densities; p-values estimated with log-rank test. Treemap showing subgroup composition based on immunoscore and
results of association analysis between immunoscore and chemotherapy response (CHT resp.), platinum resistance (Plat. Res.) and survival events (Death or
Recurrence) (C). Heatmap of unsupervised hierarchical clustering by Euclidean distance of log2CD3
+ T-cells and log2CD163
+ TAMs densities, each row represents a
patient (D). Univariable overall survival estimate (Kaplan–Meier method) of immunoscore classes (E), pairwise comparisons p-values adjusted with FDR. Forest-plot of
multivariable overall survival analysis (F). Cut-offs for CD3Hi and CD163Hi densities were set at median values for each distribution. *P < 0.05; **P < 0.01.
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FIGURE 3 | OC-IS30 identify inflamed OCs. Heatmap of Pearson R coefficients of correlation analysis between log2Immune cells densities (for CD3
+ T-cells and
CD163+ TAMs) and log2normalized Nanostring gene signature. The 30 significant correlated genes (OC-IS
30 signature) are underlined in brown (Hommel adjusted p-
values) (A). Lollipop chart showing b coefficients of the penalized ridge linear regression, in descending order based on the weight of each gene, for the prediction of
the sum of CD3+ and CD163+ density in the OCs cohort (B). Heatmap of Z-score of OC-IS30 signature in the OCs training cohort; top annotations showing histology
subtype and CD3+ T-cells and CD163+ TAMs densities (C). Scatter plot of the predicted OC-IS30 density against the observed CD3+ T-cell and CD163+ TAMs
density in the training cohort (R = 0.67, p < 0.0001) (D). Scatter plot of the OC-IS30 score against the sum of T-cell and TAMs fractions estimated by CIBERSORTx
in the TCGA cohort (R = 0.62, p < 0.0001) (E).
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BRCA1-2 mutations is reported by Kaplan–Meier curves in
Figure 4C. By exploring the TCGA datasets, we expanded our
analysis across different cancers and found that the OC-
IS30 predict favorable outcome independent from Overall Stage
and cancer site (H.R. 0.85, CI95% 0.79–0.91, p <0.0001,
Figures 4D, E).
M1-Polarized TAMs Hallmark Immune-
Infiltrated HGSC But Not T-Cell Poor CCC
Data from the literature (20) and from this study using OC-IS30
indicate a clinical benefit of the IFNg response in OCs. The
observed effect might derive from an IFNg response by tumor
cells or host immune cells, particularly TAM. To answer this
question at the single-cell level we tested the expression and
cellular localization of a set of M1- and M2-type macrophages
(Mf) markers including IRF1, IRF4, CD163, and pSTAT1Y701
by immunohistochemistry. To validate these markers for
formalin-fixed cells, we initially monitored their expression
and cellular localization on cell-block sections of monocyte-
derived macrophages. To this end, we generated monocyte-
derived (M0) Mf and polarized them to M1-type (M1IFNg and
M1IFNg+LPS) and M2-type (M2IL-4 and M2IL-10) Mf , as also
confirmed by the expression of IL6 and COX2 (Supplementary
Figure S7A, B). We found that IRF1 and pSTAT1Y701
induction and nuclear localization were strictly coupled with
M1 polarization, being limited (IRF1) or totally absent
(pSTAT1Y701) in M2IL-4 and M2IL-10 Mf (Supplementary
Figures S7C, D). On the contrary, IRF4 results strongly
modulated in M1IFNg+LPS and M2IL-4 Mf with a basal level of
nuclear expression also in M1IFNg Mf (Supplementary Figure
S7E). CD163 is induced in Mf generated by IL-10- and CSF1, as
measured by flow cytometry (21), and for this reason it has been
considered an M2-type Mf marker. We found that its
cytoplasmic expression is, however, easily detectable by IHC in
all polarization conditions (M0, M1, and M2) (Supplementary
Figure S7C), suggesting that CD163 expression is promiscuous
in Mf populations and cannot be used as M2-specific marker
by IHC.
We subsequently analyze HiOC-IS30CD163Hi (n = 15) and
LoOC-IS30CD163Lo (n = 4) from the HGSC group. In OCs
tissues, nuclear pSTAT1Y701 and IRF1 were detected in tumor
cells and cells of the microenvironment (Figure 5A). Based on a
three-tiered IHC score, we found a significant positive
correlation between protein biomarkers and the corresponding
mRNA level, as detected by Nanostring (Figure 5B). Moreover,
by double stain for CD163, we could confirm nuclear reactivity
for pSTAT1Y701 and IRF1 in a fraction of CD163+ TAMs
(Figures 5C, D). As a relevant tissue pattern, we could detect
tumor areas of “inducible” pSTAT1Y701 and IRF1 expression
containing clusters of positive tumor cells and TAMs
(Figures 5A, C). By quantitative analysis, HiOC-IS30CD163Hi
cases were significantly enriched of IRF1+ tumor cells (p = .0086)
and pSTAT1Y701+ TAMs (p = .007) compared to LoOC-
IS30CD163Lo (Figures 5E, F). This observation suggests an M1-
type polarization ofCD163+TAMs in immune-infiltratedOCs.We
extended these findings to CCC (n = 10), a subtype displaying poor
T-cells infiltration in our cohort. By double immunohistochemistry
for pSTAT1Y701 and CD163, CCC resulted largely devoid on
pSTAT1Y701+ TAMs (mean ± SD = 1.6 ± 2.0%, Figure 5D).
These observations highlight heterogeneity inM1-type polarization
in OC subtypes with diverse T-cell contexture.
M1-Type TAMs Produce CXCL10
and Co-Localize With T-Cells
Among IFNg targets, the chemokine CXCL10 has been shown to
control T-cell recruitment into the tumor environment (22). We
tested mRNA expression by using qPCR and RNAscope-based in
situ hybridization. Both approaches demonstrate that only
M1IFNg and M1IFNg+LPS were associated with high induction of
CXCL10 transcript, whereas M0, M2IL-4 and M2IL-10 Mf resulted
largely negative (Supplementary Figures S7F–G). This data was
confirmed by RNAscope-based in situ hybridization of formalin-
fixed cell-block preparation (Supplementary Figure S7F). On
biopsies, we could subsequently detect more abundant CXCL10
transcript in HiOC-IS30CD163Hi (n = 3) cases compared to
LoOC-IS30CD163Lo (n = 3) (Figure 5G). Moreover, also most
CCCs (n = 10) were largely devoid of CXCL10 stain (Figure 5H).
By combining RNAscope with IHC we could confirm a M1 Mf
identity of a fraction of CXCL10+ cells, in addition to CXCL10+
cancer cells (Figure 5I). The analysis of double stained sections
from immune infiltrated HiOC-IS30CD163Hi (n = 3) revealed that
areas containing CXCL10+ macrophages are enriched of T-cells
(Figure 5I). These findings confirmed that immune infiltrated
HiOC-IS30CD163Hi are enriched of M1-type Mf, producing the
T-cell attracting chemokine CXCL10 and surrounded by CD3+
T-cells.
A Fraction of M1-Type Mf in OCs
Co-Expresses CSF1R and TREM2
As illustrated in Supplementary Figure S4B, CSF1 mRNA
resulted significantly higher in HGSC compared to other OCs,
and its level correlated with a high density of CD163+ TAMs
(Supplementary Table S6), as also supported by in vitro
findings documenting CD163 regulation by CSF1 (21).
Moreover, CSF1R expression by Nanostring strongly
correlates with CSF1R protein expression in OCs (Figure 5B).
Previous studies have suggested expression of CSF1R on cancer
cells in OCs (23), however, our findings clearly indicate that the
expression is largely restricted to TAMs (Figure 6A). CSF1R
blockade on TAMs has obtained some meaningful level of
clinical efficacy in human cancer with high level of CSF1
(21). TAMs modulation by CSF1R blockade encompasses
a range of biological activities from depletion to their
reprogramming, the latter further amplified by CD40 agonist
(24). HiOC-IS30CD163Hi cases were significantly enriched in
pSTAT1Y701+ TAMs (p = .007) as indicated in Figures 5E, F.
By using double immunohistochemistry, we could detect a
fraction CSF1R+ TAMs expressing pSTAT1Y701, IRF1 and
CXCL10 (Figure 6B). Accordingly, also M1 type Mf
generated from peripheral blood monocytes resulted CSF1R+
by IHC (Figure 6C). We have recently reported that TREM2 is
selectively expressed on TAMs in various human cancer (25).
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FIGURE 4 | Prognostic significance of OC-IS30 in the TCGA datasets. Prognostic significance of HiOC-IS30 group by univariable (A) and multivariable (B) overall
survival analysis; Kaplan–Meier curves of the OC-IS30 status combined with BRCA1 and BRCA2 mutational status (C). Contour plots from a multivariable Cox model
analyzing samples from 9 TCGA datasets (N = 4,496) including the Overall Stage, the OC-IS30 Score [weighted log(normalized gene expression+1) applying the
coefficients defining the OC-IS30 signature (Figure 3B)] and the tumor site showing the significant, independent and additive favorable prognostic significance (color
gradient) of lower Stage (D) and higher OC-IS30 score (E) across the different tumor sites. P values estimated by log-rank test in (C) and by Cox models in (A, B, D, E).
BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; COAD, Colon adenocarcinoma; HNSC, Head and Neck squamous cell carcinoma; LUAD, Lung
adenocarcinoma; LUSC, Lung squamous cell carcinoma; OV, Ovarian serous high grade carcinoma; SKCM, Skin Cutaneous Melanoma; UCEC, Uterine Corpus
Endometrial Carcinoma. *P < 0.05; **P < 0.01.
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FIGURE 5 | IFNg polarization on cancer cells and stromal M1 type macrophages (Mf) in OCs. Sections from OCs cases and immunostained as labeled (A, C, D).
Magnification 200× (A, C; scale bar 100 um); magnification 400× (D, scale bar 50 um). Different levels of pSTAT1Y701 and IRF1 expression in LoOC-IS30CD163L and
HiOC-IS30CD163Hi HGSCs cases (A). Spearman correlogram of IRF1, pSTAT1Y701 and CSF1R in OCs by IHC and Nanostring (B). A fraction of HGSCs infiltrating
CD163+ TAMs expresses pSTAT1Y701 and IRF1 (C). Sections of CCCs showing that this tumor histotype is largely devoid of pSTAT1Y701+ TAMs (D). Heatmap
showing the IHC IRF1 and pSTAT1Y701 expression on different tissue compartments compared to the matched OC-IS30 score and log2CD163
+ density (E); Violin
plots reporting the IHC IRF1 and pSTAT1Y701 expression in the HiOC-IS30CD163Hi and LoOC-IS30CD163Lo groups, p values estimated by Mann–Whitney test (F).
(G–I) Sections from OCs immunostained or subjected to in situ hybridization as labeled; while CXCL10 is detected in HiOC-IS30CD163Hi HGSCs (G) cases it is
absent in a LoOC-IS30CD163Lo CCCs cases (H). A fraction of CXCL10+ cells is confirmed to have a M1 Mf identity and areas containing CXCL10+ macrophages
are enriched of T-cells (I). Magnification: (G, H) 200× (scale bar 100 um) and (I) 600× (scale bar 33 um, first three panels) and 400× (scale bar 50 um, right panel).
(C, D): arrowheads pointing double positive cells.
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TREM2 is expressed on CSF1R+ TAMs and is modulated by
CSF1 and its blockade on TAMs results in delayed tumor
growth, remodeling of the tumor immune contexture and
increased ICI efficacy. We found that similarly to CD163 and
CSF1R, TREM2 was also stably expressed by M1 type Mf
generated from peripheral blood monocytes by IHC
(Figure 6D). TREM2+ TAMs infiltrate HiOC-IS30CD163Hi
(Figure 6E), however, only a minor fraction of them co-
expressed pSTAT1Y701, IRF1 and CXCL10 (Figure 6F). All
these findings indicate that appropriate characterization of Mf
on OCs requires modified approaches and might help in patient
selection to CSF1R- and TREM2-blockade alone in combination
with existing ICI.
M1-Type Mf Polarization Occurs Across
MfSubsets and Cancer Types
We found that the prognostic power of HiOC-IS30 extend to
various cancer types (Figures 4D, E). By using double
immunohistochemistry for CD163 and pSTAT1Y701, we
screened a set of human cancers including melanomas (n = 4),
head and neck squamous cell carcinomas (n = 8), MSI+ colorectal
carcinomas (n = 4), MSI+ endometrial carcinomas (n = 4), breast
carcinomas (n = 8) and lung carcinomas (n = 4). A significant
fraction of these cancers contained CD163+pSTAT1Y701+ M1-
type Mf producing CXCL10 and surrounded by CD3 T-cell
infiltration (Supplementary Figures S8A, B). These data extend
our OCs findings across human cancer types.
Recent high dimensional studies of human tumor-associated
myeloid cells have led to the identification of discrete TAM
subsets based on their transcriptional profile. Specifically,
emerging mononuclear phagocytes subsets in cancer are
distinct on the basis of their ontogeny, differentiation state,
functional orientation, proliferation potential and predictive
power in response to ICI treatments (26, 27). To gain further
insight on the transcriptional profile of M1-polarized TAMs in
various cancer types we explored a pan-cancer scRNAseq dataset
[n = 36; (19)] comprising ovarian HGSC, breast, lung and
colorectal cancers. To this end, we merged 37,334 myeloid cells
from all cancer types. Louvain Graph-based clustering at the
resolution 0.6 identified 27 clusters of mononuclear phagocytes
(Figure 7A). Among CD68+CD163+ TAMs also expressing the
recently identified TREM2 marker, we could identify a
CXCL10+IRF1+STAT1+ M1-type Mf population (Cluster 9)
(Figures 7A, B) shared between all cancer types (Figure 7C).
We next performed differential gene expression analysis between
the CXCL10+IRF1+ TAM cluster (cluster 9) and the rest of the
myeloid cells. Gene pathway analysis showed that transcripts
enriched in cluster 9 were involved in interferon signaling as well
as in MHC-dependent antigen processing and in cross
presentation (Figure 7D and Supplementary Table S7,
Supplementary Figure S9). Altogether, these results show that
M1-polarized TAMs form a functionally distinct subset of TAMs
infiltrating various types of cancers. These M1-polarized TAMs
are part of a T-cell infiltrated immune contexture positively
correlating with better clinical outcome.
DISCUSSION
This study reports the characterization of the immune
contexture in OCs, by digital microscopy analysis of a
retrospective institutional cohort. Heterogeneity in terms of
CD3+ T-cell and CD163+ Mf infiltration emerged among OC
subtypes, including immune-infiltrated HGSC and T-cell poor
CCC. Immune-infiltrated HGSC display high density of CD3+T-
cells and of CD163+ TAMs associated with favorable clinical
features and response to chemotherapy or platinum sensitivity.
Gene expression analysis by using OC-IS30 immune signature
generated from our institutional cohort and extended to the OV-
TCGA dataset (6), uncovers the existence of a clinically
meaningful functional immune response, particularly in the
BRCA mutated subgroup. Immune-infiltrated HGSC contain
CXCL10-producing IFNg-polarized M1-type Mf surrounded
by T-cells also expressing GZMB, indicating ongoing
spontaneous T-cell response. All these findings were extended
to and confirmed in other immunogenic human cancers types.
The clinical relevance of the endogenous immune response to
ovarian carcinoma (OC), and specifically the favorable
prognostic effect of CD3+ T-cells and CD8+ T-cells have been
suggested by a set of observation from pre-clinical and clinical
studies (13) and confirmed by a recent meta-analysis (15).
Endogenous specific T-cell response has been documented in
OCs. Neo-epitope specific CD8+ T-cells and CD4+ T-cells were
identified both in peripheral blood and among TILs in
immunotherapy-naïve OCs (28). Data on the role of Mf are
less consistent. Early studies indicate that Mf purified from OCs
ascites display functional heterogeneity (29), a finding consistent
with distinct Mf polarizations associated to a bivalent behavior
(30). In immune infiltrated OCs, the density of CD3+ T-cells
correlates with the density of CD163+ TAMs and the two cell
types resulted intermingled, suggesting their functional
interaction. Of note, we found that a fraction of M1-type TAM
in OCs produce abundant CXCL10, likely representing one of the
relevant T-cell attracting chemokines in this neoplasm. To the
other side of the spectrum, we identified a consistent subgroup of
CCC containing macrophage deficient in M1-type polarization
and lacking T-cell infiltration. CCC are distinct from HGSC in
terms of molecular profile and response to systemic treatments;
this study highlights distinct features also in terms of immune
ecosystem likely accounting for their clinical behavior. Novel
treatment options for CCC should consider these findings for a
proficient bypass of the T-cell exclusion mechanisms.
The role of Mf in cancer immune surveillance is rapidly
evolving (31, 32). In progressively growing cancer, TAMs
modulate tumor progression by regulating various tumor-
promoting functions including immunosuppression,
angiogenesis, tumor cell proliferation, and stromal infiltration.
However, recent findings indicate that similarly to other innate
immune cells (33), human TAMs display a significant plasticity
(34) as also confirmed by recent high dimensional analysis (26,
27). IFNg-dependent M1 polarization can be mediated by
neighboring T-cells, as observed in this study, or by NK cells
(35). M1 Mf initiates pro-inflammatory responses and promotes
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direct or T-cell mediated antitumor effector functions (34, 36)
particularly in highly immunogenic cancer (35). This plasticity
accounts for a different prognostic relevance associated of TAMs.
Based on this dichotomy, major approaches targeting these cells
are exploring novel paradigms such as TAMs reprogramming in
addition to their depletion and recruitment blockade, as for
CSF1R blockade (21, 24). Various biomarkers have been







FIGURE 6 | CSF1R and TREM-2 expression in OCs. Sections from HGSCs cases (A, B, E, F) and from cell-block preparations of polarized monocyte-derived Mf
(C, D) immunostained as labeled. Magnification 200× (A, E; scale bar 100 um) and 400× (B, F, scale bar 50 um). CSF1R expression in OCs is largely restricted to
TAMs (A). Double immunohistochemistry showing co-expression of pSTAT1Y701, IRF1 and CXCL10 in CSF1R+ TAMs (B). M1 type and M2 type Mf generated
from peripheral blood monocytes express CSF1R (C). M1 type Mf generated from peripheral blood monocytes express TREM2 (D). TREM2 is expressed on TAMs
in HGSCS. TREM2+ TAMs detected in HiOC-IS30CD163Hi (E); a fraction of TREM2+ TAMs co-expressed pSTAT1Y701, IRF1 and CXCL10 (F).
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archival tissue (37). By single-cell analysis of FFPE sections, this
study identifies M1-type TAMs based on in vitro modeling of
monocyte-derived M1IFNg and M1IFNg+LPS. OCs-associated M1-
type TAMs resulted CXCL10+IRF1+ STAT1p+. Data analysis of
scRNAseq pan-cancer dataset confirmed the existence of a
CXCL10+IRF1+ STAT1+ M1-type Mf across human cancers
displaying activation of antigen presenting and cross presentation
gene programs. IRF1 represents a crucial transcriptional regulator
of the IFNg-response (38) and recent findings on human cancers
identified IRF1 as a central hub in cancer immunity (39).
In macrophages, IRF1 drives M1 polarization (39) by increasing
the expression of pro-inflammatory cytokines and chemokines
(40). In addition, IRF1+ Mf displays a tumoricidal activity (41)





FIGURE 7 | scRNAseq analysis of myeloid cells across cancer types. In (A) is shown the experimental design from published dataset: scRNAseq of myeloid cells
(left panel). Dimensionality reduction of scRNAseq data merged from lung, colorectal, ovarian and breast tumors was performed using a Louvain graph-based
clustering identifying 27 clusters (middle panel). Each dot represents an individual cell (n = 37,334). Violin plots illustrating expression distributions among the 27
clusters of CXCL10 (right panel). UMAP plot showing expression of CD68, CD163, TREM2, CXCL10, STAT1 and IRF1 (B). Proportion of cells of the CXCL10+
cluster 9 per tumor type (C); BC, breast cancer; CRC, colorectal cancer. Reactome pathway analysis for genes characterizing cluster 9 (adjusted P value <0.05) (D).
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enzyme DICER is significantly down-modulated by IFNg. Of note,
STAT1+IRF1+ TAM have been observed in tumor-bearing mice
with DICER conditional deletion (42) and resulted in tumor
inhibition by recruitment of activated CTL.
Immune infiltrated HGSC are defined by CD3HiCD163Hi
immunoscore and display a better outcome, independently from
other major prognosticators. Immune infiltrated HGSC are also
enriched of OC-IS30. The immune cell component plays a relevant
role in the clinical response to various HGSC treatments (43). The
primary systemic treatments include chemotherapy with
platinum-based regimens combined with taxanes. Of note,
outcomes of platinum-based regimen are significantly
dependent on the existing tumor immune microenvironment
(44). In the last few years, Poly (ADP-ribose) polymerase
(PARP) inhibitors have been included for HGSC showing HRD.
Several trials demonstrated the efficacy of these compounds both
as maintenance therapy after first-line chemotherapy (8, 45) or
after the treatment of recurrent disease. The best performance for
PARP inhibitors is observed in tumors with BRCA1 or BRCA2
mutation or with at least an HRD phenotype. A recent meta-
analysis confirmed their efficacy with improvement of PFS in
platinum-sensitive recurrent OC (7). The findings presented here
indicate that a proficient immune microenvironment predicts a
better outcome. BRCA1 and BRCA2 mutated tumors are also
densely infiltrated by T-cells, however, we found that the
prognostic effect of the OC-IS30 signature, as tested in the
TCGA cohort, is independent and additive from BRCA status
and others prognosticator (Figure 4B).
The role of immunotherapy in OCs has been recently
investigated by testing the efficacy of ICI (anti-PD1 or anti-
PDL1) as single therapy. The results of the first trials with ICIs
(46) showed a fair effectiveness. However, the recent combination
of ICIs and PARPi provided better results (11, 47). The best results
obtained applying ICIs in the subgroup of BRCA1 or BRCA2
mutated patients can be explained by recent studies showing that
PD1 and PDL1 are highly expressed in BRCA1 or BRCA2mutated
patients. Moreover, PARPi administration to breast cancer cell
lines further enhance PD-L1 by inactivating GSK3b (48), thus
explaining the benefit obtained by the combination of PARPi and
anti-PD-L1 therapy (11). It should be reminded that, particularly
inHGSC,PD-L1 is primarily expressed bymacrophages and that a
high density of PD-L1+ Mf correlates with CD8+ T-cells and
predicts favorable survival (49). The cellular source and the
magnitude of expression of PD-L1 might variably dictate its
immune escape potency (50). Based on our findings, it is highly
likely that the major source of PD-L1 in OC is from innate
immune resistance mechanisms with its dominant hub on M1-
type TAMs, whose fine-tuned modulation might further enhance
the clinical benefit. These findings identify the combined analysis
of immune-contexture and immune signatures as a novel
biomarker in OCs management, to be further investigated in the
predictive setting.
In conclusion, the results of this study document a proficient
immune contexture in a subgroup of primary OCs. Findings
proposed here are in keeping with a relevant role of the innate
TAMs compartment in OCs immune surveillance, likely
unleashing the endogenous adaptive T-cell response. However,
T-cell exclusion occurs also in OCs, particularly in the CCC
subtype, likely as a result of the lack of CXCL10+-producing M1-
type Mf. Since CCC is already infiltrated by macrophages, their
repolarization to a CXCL10+TAM might provide a clinical
benefit. As an extension of this analysis, M1-type Mf sharing a
common transcriptional activation state were also detected
across various human immunogenic cancers. However,
intratumor heterogeneity in TAM polarization emerged in this
study, with also a fraction of CSF1R and TREM2 M1-type Mf.
This indicates that using approaches targeting molecules of
immunosuppressive myeloid cells such as CSF1R and TREM2
would partially affect the endogenous anti-tumor TAM
component. Instead, implementation of reprogramming
approaches that further bolster the already present macrophage
component is needed.
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8. González-Martıń A, Pothuri B, Vergote I, DePont Christensen R, Graybill W,
Mirza MR, et al. Niraparib in Patients With Newly Diagnosed Advanced
Ovarian Cancer. N Engl J Med (2019) 381:2391–402. doi: 10.1056/
NEJMoa1910962
9. Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, et al.
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the
Treatment of Solid Tumors. Antibodies (2019) 8:51. doi: 10.3390/
antib8040051
10. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-
Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade-Based
Immunotherapy. Science (80-) (2018) 362:363(6430). doi: 10.1126/
science.aar3593. Erratum in: Science.
11. Drew Y, de Jonge M, Hong SH, Park YH, Wolfer A, Brown J, et al. An Open-
Label, Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA):
Results in Germline BRCA -Mutated (Gbrca M) Platinum-Sensitive Relapsed
(PSR) Ovarian Cancer (OC). Gynecol Oncol (2018) 149:246–7. doi: 10.1016/
j.ygyno.2018.04.555
12. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C,
et al. Type, Density, and Location of Immune Cells Within Human Colorectal
Tumors Predict Clinical Outcome. Science (80-) (2006) 313:1960–4.
doi: 10.1126/science.1129139
13. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani
G, et al. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian
Cancer. N Engl J Med (2003) 348:203–13. doi: 10.1056/NEJMoa020177
14. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial
CD8+ Tumor-Infiltrating Lymphocytes and a High CD8+/Regulatory T Cell
Ratio Are Associated With Favorable Prognosis in Ovarian Cancer. Proc Natl
Acad Sci USA (2005) 102:18538–43. doi: 10.1073/pnas.0509182102
15. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic
Significance of Tumor-Infiltrating T Cells in Ovarian Cancer: A Meta-
Analysis. Gynecol Oncol (2012) 124:192–8. doi: 10.1016/j.ygyno.2011.09.039
16. Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, et al.
Curatedovariandata: Clinically Annotated Data for the Ovarian Cancer
Transcriptome. Database (2013) 2013:bat013. doi: 10.1093/database/bat013
17. Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al.
Determining Cell Type Abundance and Expression From Bulk Tissues With
Digital Cytometry. Nat Biotechnol (2019) 37:773–82. doi: 10.1038/s41587-
019-0114-2
18. Essers PBM, van der HeijdenM, Vossen D, de Roest RH, Leemans CR, Brakenhoff
RH, et al. Ovarian Cancer Derived Copy Number Alterations Signatures Are
Prognostic in Chemoradiotherapy Treated Head and Neck Squamous Cell
Carcinoma. Int J Cancer (2020) 147:1732–9. doi: 10.1002/ijc.32962
19. Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E, et al. A Pan-Cancer
Blueprint of the Heterogeneous Tumor Microenvironment Revealed by
Single-Cell Profiling. Cell Res (2020) 30:745–62. doi: 10.1038/s41422-020-
0355-0
20. Cardenas H, Jiang G, Thomes Pepin J, Parker JB, Condello S, Nephew KP,
et al. Interferon-g Signaling Is Associated With BRCA1 Loss-of-Function
Mutations in High Grade Serous Ovarian Cancer. NPJ Precis Oncol (2019)
3:1–14. doi: 10.1038/s41698-019-0103-4
21. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting
Tumor-Associated Macrophages With Anti-CSF-1R Antibody Reveals a
Strategy for Cancer Therapy. Cancer Cell (2014) 25:846–59. doi: 10.1016/
j.ccr.2014.05.016
22. House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-
Derived CXCL9 and CXCL10 are Required for Antitumor Immune Responses
Following Immune Checkpoint Blockade. Clin Cancer Res (2020) 26(2):487–
504. doi: 10.1158/1078-0432.CCR-19-1868
23. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of
Epithelial Macrophage Colony-Stimulating Factor (CSF-1) and CSF-1
Receptor: A Poor Prognostic Factor in Epithelial Ovarian Cancer,
Contrasted With a Protective Effect of Stromal CSF-1. Clin Cancer Res
(1997) 3:999–1007.
24. Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, et al. Rapid
Activation of Tumor-Associated Macrophages Boosts Preexisting Tumor
Immunity. J Exp Med (2018) 215:859–76. doi: 10.1084/jem.20171440
25. Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Jingqin L, et al. TREM2
Modulation Remodels the Tumor Myeloid Landscape, Enhancing Anti-PD-1
Immunotherapy. Cell (2020) 182:P886–900.E17. doi : 10.1016/
j.cell.2020.07.013
26. Qu Y, Wen J, Thomas G, YangW, Prior W, HeW, et al. Baseline Frequency of
Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts
Response to Avelumab Treatment. Cell Rep (2020) 32:108115. doi: 10.1016/
j.celrep.2020.108115
27. Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K,
et al. Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and
Response to Immune Checkpoint Blockade. Immunity (2020) 53:1215–29.
doi: 10.1016/j.immuni.2020.10.020
28. Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, et al. Sensitive
and Frequent Identification of High Avidity Neo-Epitope Specific CD8+
T Cells in Immunotherapy-Naive Ovarian Cancer. Nat Commun (2018)
9:1–10. doi: 10.1038/s41467-018-03301-0
29. Mantovani A, Peri G, Polentarutti N, Bolis G, Mangioni C, Spreafico F. Effects
on In Vitro Tumor Growth of Macrophages Isolated From Human Ascitic
Ovarian Tumors. Int J Cancer (1979) 23:157–64. doi: 10.1002/ijc.2910230204
30. Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W, et al. Prognostic Significance of
Tumor-Associated Macrophages in Ovarian Cancer: A Meta-Analysis.
Gynecol Oncol (2017) 147:181–7. doi: 10.1016/j.ygyno.2017.07.007
31. Lewis CE, Harney AS, Pollard JW. The Multifaceted Role of Perivascular
Macrophages in Tumors. Cancer Cell (2016) 30:18–25. doi: 10.1016/
j.ccell.2016.05.017
32. Gordon S, Martinez FO. Alternative Activation of Macrophages: Mechanism
and Functions. Immunity (2010) 32:593–604. doi: 10.1016/j.immuni.
2010.05.007
33. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of
Tumor-Associated Neutrophil Phenotype by TGF-Beta: “N1” Versus “N2”
Tan. Cancer Cell (2009) 16:183–94. doi: 10.1016/j.ccr.2009.06.017
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